Lyell Immunopharma, Inc.
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
•Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2…